Partnership establishes grant to advance urology research in Canada
MARKHAM, ON, March 28, 2012 /CNW/ - The Canadian Urological Association
(CUA) and Astellas Pharma Canada, Inc. have announced the creation of a
research alliance aimed at advancing research and patient care in the
field of urology. Astellas Pharma Canada has pledged $750,000 over a
period of five years to support Canadian investigators in urology. The
objective of the CUA Astellas Research Grant Program is to support
peer-reviewed research that promotes excellence in urological research
with the ultimate goal of improving patient care.
"Urology research has been generally under-funded in Canada," says Dr.
Sender Herschorn, BSc, MDCM, FRCSC, Past President, Canadian Urological
Association. "Astellas' contribution to research and development truly
demonstrates the company's continued commitment to urology in Canada.
Most significantly, it will help us to address gaps in patient care.
This is very important to the CUA."
Specifically, the CUA's mission is to represent and provide a voice for
all Canadian urologists and to foster dedication of all members of the
profession toward ensuring the highest possible standard of urologic
care for Canadians.
The Grant Program reflects the CUA's commitment to thought leadership,
practice excellence and life-long learning, explains Dr. Ricardo
Rendon, Chair of Scientific Council of Canadian Urological Association
Scholarship Fund (CUASF). "The support provided by this Grant Program
will help us tackle some of the questions we haven't previously had the
resources to take on. We are hopeful this program will have a positive
and real impact on clinical practice."
The primary focus of the Grant Program is to support research in
functional urology such as overactive bladder (OAB), lower urinary tract symptoms (LUTS), pelvic floor disorders, voiding dysfunctions, neurogenic
bladder, etc. The secondary focus is to support other urology areas
such as urologic cancer, other community-based research, etc. Grant
recipients are expected to demonstrate improved understanding of the
specific research area and/or contribute to improving patient care.
"Urology is a priority therapeutic area for Astellas," said Michael
Tremblay, President, Astellas Pharma Canada, Inc. "We have an
unwavering commitment to patients suffering from urologic conditions
and to the medical professionals who treat them. As a research-based
company we understand the responsibility that falls to industry to
support Canadian research, therefore we're delighted to collaborate
with the CUA and are confident that the outcome of this research will
ultimately lead to improved therapies and quality of life."
About the Canadian Urology Association (CUA)
The CUA Mission is to represent and provide a voice for all Canadian
urologists and to foster dedication of all members of the profession
toward ensuring the highest possible standard of urologic care for
The goals of the CUA are to
To foster and promote excellence in urologic practice through education
To provide leadership in promoting evidence based clinical practice
through the development of practice guidelines
To foster and promote life-long learning by Canadian urologists through
continuous professional development
To provide leadership in public education for urologic diseases
To represent Canadian urology in developing and fostering partnerships
while maintaining the highest educational and ethical standards
To represent the Canadian urologic community in relationships with
national and international medical societies
More information about CUA can be found at www.cua.org.
About Astellas Pharma Canada, Inc. Astellas Pharma Canada, Inc., a Canadian affiliate of Tokyo-based
Astellas Pharma Inc. ("Astellas"), is a pharmaceutical company
dedicated to changing tomorrow by improving the health of people around
the world through innovative and reliable pharmaceutical products.
Astellas has an intense focus on five key therapeutic areas - Urology,
Immunology including Transplantation and Infectious Diseases, Oncology,
Neuroscience and Diabetes Mellitus (DM) Complications and Metabolic
Diseases. Astellas is considered a leader in these fields. For more
information about Astellas Pharma Canada, Inc., please visit www.astellas.ca
SOURCE Astellas Pharma Canada, Inc.
For further information:
tel: 416.425.9143 x17
toll-free: 1.866.337.3362 x17